CA3185812A1 - Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same - Google Patents

Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Info

Publication number
CA3185812A1
CA3185812A1 CA3185812A CA3185812A CA3185812A1 CA 3185812 A1 CA3185812 A1 CA 3185812A1 CA 3185812 A CA3185812 A CA 3185812A CA 3185812 A CA3185812 A CA 3185812A CA 3185812 A1 CA3185812 A1 CA 3185812A1
Authority
CA
Canada
Prior art keywords
antibody
fgfr2
polypeptide
antigen binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3185812A
Other languages
English (en)
French (fr)
Inventor
Saireudee Chaturantabut
William Sellers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3185812A1 publication Critical patent/CA3185812A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3185812A 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same Pending CA3185812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033975P 2020-06-03 2020-06-03
US63/033,975 2020-06-03
PCT/US2021/035468 WO2021247718A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Publications (1)

Publication Number Publication Date
CA3185812A1 true CA3185812A1 (en) 2021-12-09

Family

ID=78829919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3185812A Pending CA3185812A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Country Status (7)

Country Link
US (1) US20230295308A1 (https=)
EP (1) EP4161566A4 (https=)
JP (1) JP2023528454A (https=)
CN (1) CN116367855A (https=)
AU (1) AU2021284297A1 (https=)
CA (1) CA3185812A1 (https=)
WO (1) WO2021247718A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2025070733A1 (en) * 2023-09-29 2025-04-03 Chugai Seiyaku Kabushiki Kaisha Anti-rtk antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
CA2961439A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
MX2019005552A (es) * 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.

Also Published As

Publication number Publication date
EP4161566A1 (en) 2023-04-12
US20230295308A1 (en) 2023-09-21
WO2021247718A1 (en) 2021-12-09
AU2021284297A1 (en) 2023-02-02
JP2023528454A (ja) 2023-07-04
CN116367855A (zh) 2023-06-30
EP4161566A4 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
CN112912396B (zh) 抗cldn18.2抗体及其用途
CN102459346B (zh) 制造异源多聚体分子的方法
TW202019465A (zh) 抗ｔｉｇｉｔ抗體及其用途
US11434482B2 (en) Methods of identifying bacteria comprising binding polypeptides
KR101589391B1 (ko) 항-ｅｐｈｂ４ 항체 및 그의 사용 방법
KR20110081812A (ko) 다중특이적 항체
KR101617108B1 (ko) 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
CA3185812A1 (en) Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
EP4596582A1 (en) B7-h3 binding protein and use thereof
IL323270A (en) Antibody against PTK7 and its uses
KR20250028265A (ko) 항체 및 이의 용도
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
JP2025512671A (ja) Ｈｅｒ３結合タンパク質及びその使用
EP4506361A1 (en) Antibody against c-met and use thereof
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
WO2024173565A2 (en) Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
JP2024534824A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
TW202540201A (zh) Adam9結合蛋白及其用途
WO2026052582A1 (en) Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3
CN121226558A (zh) Ceacam5结合蛋白及其用途
CN118165107A (zh) 结合tigit的抗体分子
HK40110414A (zh) 抗her2抗体及其使用方法
KR20200138013A (ko) 엔도텔린 수용체 a 결합력이 향상된 항체
HK40042152B (zh) 抗tigit抗体及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250529

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250602

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250819

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250819

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250819

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250819